Microscopic polyangiitis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 12: Line 12:
   MeshID        = |
   MeshID        = |
}}
}}
{{Churg-Strauss syndrome}}
{{Microscopic polyangiitis}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
{{CMG}}{{APM}}{{AE}}{{KW}}{{CZ}}


{{SK}} MPA
{{SK}} MPA
==[[Microscopic polyangiitis overview|Overview]]==
==[[Microscopic polyangiitis historical perspective|Historical Perspective]]==
==[[Microscopic polyangiitis classification|Classification]]==
==[[Microscopic polyangiitis pathophysiology|Pathophysiology]]==
==[[Microscopic polyangiitis causes|Causes]]==
==[[Microscopic polyangiitis differential diagnosis|Differentiating Any Disease from other Diseases]]==
==[[Microscopic polyangiitis epidemiology and demographics|Epidemiology and Demographics]]==
==[[Microscopic polyangiitis risk factors|Risk Factors]]==
==[[Microscopic polyangiitis screening|Screening]]==
==[[Microscopic polyangiitis natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
==Diagnosis==
[[Microscopic polyangiitis history and symptoms|History and Symptoms]] | [[Microscopic polyangiitis physical examination|Physical Examination]] | [[Microscopic polyangiitis laboratory findings|Laboratory Findings]] | [[Microscopic polyangiitis electrocardiogram|Electrocardiogram]] | [[Microscopic polyangiitis chest x ray|Chest X Ray]] | [[Microscopic polyangiitis CT|CT]] | [[Microscopic polyangiitis MRI|MRI]] | [[Microscopic polyangiitis echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Microscopic polyangiitis other imaging findings|Other Imaging Findings]] | [[Microscopic polyangiitis other diagnostic studies|Other Diagnostic Studies]]
==Treatment==
[[Microscopic polyangiitis medical therapy|Medical Therapy]] | [[Microscopic polyangiitis surgery|Surgery]] | [[Microscopic polyangiitis primary prevention|Primary Prevention]] | [[Microscopic polyangiitis secondary prevention|Secondary Prevention]] | [[Microscopic polyangiitis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Microscopic polyangiitis future or investigational therapies|Future or Investigational Therapies]]
==Case Studies==
[[Microscopic polyangiitis case study one|Case #1]]
==Overview==
==Overview==
'''Microscopic polyangiitis (MPA) ''' is an ill-defined [[autoimmune disease]] characterized by pauci-immune, necrotizing, small-vessel [[vasculitis]] without clinical or pathological evidence of necrotizing granulomatous [[inflammation]]. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.
'''Microscopic polyangiitis (MPA) ''' is an ill-defined [[autoimmune disease]] characterized by pauci-immune, necrotizing, small-vessel [[vasculitis]] without clinical or pathological evidence of necrotizing granulomatous [[inflammation]]. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.

Revision as of 13:34, 23 November 2016

Microscopic polyangiitis
ICD-10 M31.7
DiseasesDB 8193

Microscopic polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microscopic polyangiitis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis

CDC on Microscopic polyangiitis

Microscopic polyangiitis in the news

Blogs on Microscopic polyangiitis

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]Cafer Zorkun, M.D., Ph.D. [4]

Synonyms and keywords: MPA

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Any Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1


Overview

Microscopic polyangiitis (MPA) is an ill-defined autoimmune disease characterized by pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation. Because many different organ systems may be involved, a wide range of symptoms are possible in MPA.

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Cause

This condition, the clinical picture of which may include many features of systemic lupus erythematosis, has been reported to have been caused by antibiotics and also by certain infections, though, as with many autoimmune diseases, the causes remain to a large extent unknown.

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic criteria

History and Symptoms

Physical examination

Laboratory findings

Laboratory tests show an increased sedimentation rate, reduced red blood count, antineutrophil cytoplasmic antibodies (p-ANCA) directed against [MPO(a constituent of neutrophil granules), and protein and red blood cells in the urine.

The test for anti-glomerular basement membrane antibody (GBM), which is positive in Goodpasture's syndrome, is negative.

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

The customary treatment involves long term dosage of prednisone, alternated or combined with cytotoxic drugs, such as cyclophosphamide or azathioprine. Plasmapheresis may also be indicated in the acute setting to remove ANCA antibodies.

Surgery

Prevention

References

Related Chapters

Template:Diseases of the musculoskeletal system and connective tissue de:Mikroskopische Polyangiitis nl:Microscopische polyangiitis


Template:WikiDoc Sources